On this mornings opening bell, IMGN started at $16.17, 74cents below it's after market surge on Thursday.
This only confirms the "stay away from the after market strategy". Some years back I do remember Biogen making a offer to buy out Idec and a awesome increase in the after market on a Friday was about 70%.
IMGN went up 91 cents to $16.95 in the after hours trading on 7200 shares. Lets all take a guess at what the opening price will be at 9:30. My bet is it will open at $16.04 LOL
It would be a thrill to see the board members buy shares in our company. The CEO and other key people keep getting stock rights. Mr Lambert is the one who currently deserves all the others stock options given out.
Your speculation that Roche might be thinking about buying Immunogen could be right on. In this mornings WSJ on page B3, there is a feature story, "Roche is Ripe for Deals as Genentech Debt Falls". It states that Roche Holding will have more flexibility to pursue acquisitions in the coming year as the Swiss drug maker pays off the bulk of debt from its 47 billion buyout of Genentech.
Thank you Slumdawg. Good information. You and CH have been very good posters on this board. I'm just a High School graduate (-:
I always thought that IDEC developed Rituxan and later got bought out by Biogen to become Biogen/Idec.
Sgen has been a winner big time for patient investors since 2007. Even horses need a rest (-:
but stop and look how it has been a dramatic northern movement despites some of the so called pros who have missed the boat and are embarrassed with their predictions.
Not worried about each days high and lows with this company that is heading north over time.
Long term patience mixed in with $ cost averaging has made me a multi- Mill
The wolfs of Wall st. are losers and give capitalism a bad rap. Stick with good companies that will raise their dividends each year and plow their money back into research and you will be rewarded.....forget "Fast Money".....it can raise your blood pressure. God Bless America (-:
$ cost averaging has never hurt anyone, especially over the long term. Many posters here have bought Imgn at 2 etc.. SGEN was another good $ cost avg. over time.
Old fashioned Boeblingen
In the February 2014 Fortune Magazines 100 top companies to work for, Genentech is listed number 6. It goes on to say " The staff at the biotech giant is inspired by patient stories. When a new drug got FDA approval last February, employees pulled out all the stops to ship the drug overnight to the UCLA Medical Center, where they had heard three women were desperately awaiting treatment.
Its still all about people and how they are treated and Genentech gives their employees the perks of Paid Sabbaticals, compressed work weeks, job sharing and onsite child care.....people come first.
Bioman, Never say never. Have been in the market since 1960 and when you least expect it, things happen on the up and down. Also Debbie downers and Charlie Uppers can have a 50-50 chance of being 100% right.
Good point Chris. Actually too many investors are hyper and if they have a problem with top dogs running the co. they should invest in other names. One fellow named Oppy or Top exec. is such a Top Downer on IMGN he should cut out to prevent high blood pressure and living on line to make his complaint posts every hour on Investor Village.
Frankly Charlotte, I don't give a damn.
If they made a profit of 25 cents a share, it would go down 10%.
In any event, Merry Christmas.